Abstract:This prospective cohort study measured anti-Müllerian hormone (AMH) levels in recurrent miscarriage (RM) patients, compared them to a normal population, and assessed the pregnancy outcomes. The RM patients demonstrated AMH levels that were significantly lower than the normal population, both in women aged ≤35 years, and those aged >35 years. AMH percentiles were found to be significantly lower in the study group of RM patients ≤35 years (p< .004) in the 5th and 50th percentiles, and in all percentiles in women >35 years (p< .03), were compared to women from a normal population. Serum AMH levels may reflect quality, and quantity of the remaining oocytes in these patients, and RM patients may have a low ovarian reserve, and a potentially poor oocyte quality, as shown by low circulating AMH. The evaluation of AMH levels in a RM work up may allow realistic counselling and possible ART referral in RM patients. Impact statement What is already known on this subject? There is some evidence to show that low AMH levels are associated with recurrent miscarriages and this is thought to be due to a decreased oocyte quality. The AMH levels are lower in the patients with endometriosis, and are often significantly higher in the patients with polycystic ovarian syndrome. Both conditions are independently associated with miscarriages. What the results of this study add? Anti-Müllerian hormone (AMH) levels were found to be significantly lower in recurrent miscarriage patients, compared to a normal population. This may be another factor contributing to miscarriages. The spontaneous pregnancy rates in the miscarriage group significantly improved with increasing AMH levels. This may confirm that patients with low AMH levels have poorer quality oocytes, and thus may be considered 'sub-fertile'. It was also found that the utilisation of assisted reproductive technologies (ART) to achieve a pregnancy was significantly reduced in the groups with a higher serum AMH. What the implications are of these findings for clinical practice and/or further research? Serum AMH levels should be offered to all patients as part of a recurrent miscarriage work up. Detecting the low AMH levels and counselling the patients on these findings may allow them the option of accessing ART. ART may have the ability to expedite conception rates, and with pre-implantation genetic analyses, could possibly select the embryos with the greatest chance of survival. Further research is needed to establish how the decreased AMH levels contribute to recurrent miscarriages.

Impact of radiation on serum anti-Müllerian hormone during hysterosalpingography in female infertility

Anti-Müllerian hormone for prediction of ovarian response in Chinese infertile women undergoing IVF/ICSI cycles: a prospective, multi-centre, observational study

Predictive Value of the Serum Anti-Müllerian Level for Spontaneous Pregnancy in Women after Endometriosis Surgery

Post-treatment anti-Mullerian hormone (AMH) levels predict long-term ovarian dysfunction in women with hematological malignancies

Serum Levels of Anti-Müllerian Hormone Influence Pregnancy Outcomes Associated with Gonadotropin-Releasing Hormone Antagonist Treatment: a Retrospective Cohort Study

History of infertility and anti-Müllerian hormone levels among participants in the Nurses' Health Study II

Diagnostic Approaches in Nuclear Medicine for Reproductive Health Assessment: Hysterosalpingography in Radiology versus hysterosalpingoscintigraphy

Serum Anti-Müllerian Hormone Levels Are Associated with Perinatal Outcomes in Women Undergoing IVF/ICSI: A Multicenter Retrospective Cohort Study.

A Retrospective Analysis of the Effect of Salpingectomy on Serum Antimüllerian Hormone Level and Ovarian Reserve.

Lower serum AMH concentration is correlated with serum IgG1 decreased in the infertile woman: A real-world retrospective study

High anti-Müllerian hormone levels might not reflect the likelihood of clinical pregnancy rate in IVF/ICSI treatment

Impairment of Ovarian Function and Serum AMH by Unilateral Salpingectomy

The impact of high circulating anti-müllerian hormone on endometrial thickness and outcome of assisted reproductive technology in women with polycystic ovarian syndrome: A cohort study

Serum anti-Müllerian hormone levels are associated with early miscarriage in the IVF/ICSI fresh cycle

Anti-Müllerian hormone levels in recurrent embryonic miscarriage patients are frequently abnormal, and may affect pregnancy outcomes

High anti-Mullerian hormone levels might not reflect the likelihood of clinical pregnancy rate in IVF/ICSI treatment

Effect of laparoscopic endometrioma cystectomy on anti-Müllerian hormone (AMH) levels

Iodine and other factors associated with fertility outcome following oil-soluble contrast medium hysterosalpingography: a prospective cohort study

High Anti-Müllerian Hormone (AMH) is Associated with Increased Risks of Ectopic Pregnancy in Women Undergoing Fresh Embryo Transfer Cycle, a Cohort Study

Anti-Mullerian Hormone (AMH) Level in Presence of Ovarian Endometrioma

Serum Antimüllerian Hormone is Lower in Patients with Multiple Radioiodine Dose for Treatment of Pediatric Thyroid Cancer